Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes late-stage clinical products in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; and BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma. This segment also provides various consulting...